女性性功能障碍的影响因素研究

doi:10.3969/j.issn.1006-7795.2022.03.005

首都医科大学学报 ›› 2022, Vol. 43 ›› Issue (3): 357-363.doi: 10.3969/j.issn.1006-7795.2022.03.005

• 更年期妇科内分泌与生育力保护 • 上一篇下一篇

女性性功能障碍的影响因素研究

鞠蕊^1,2, 阮祥燕^1*, 代荫梅^1,2, 白勇涛³, 杨瑜¹, 许新¹, 程姣姣¹, 杨幸子³, 施琰红³, 孙艳华⁴, 李瑞玲⁴

1.首都医科大学附属北京妇产医院/北京妇幼保健院内分泌科,北京100026;
2.首都医科大学附属北京妇产医院/北京妇幼保健院药物临床试验机构办公室,北京100026;
3.北京市朝阳区太阳宫社区卫生服务中心妇科,北京100028;
4.北京市朝阳区妇幼保健院妇科,北京100022

收稿日期:2022-02-26 出版日期:2022-06-21 发布日期:2022-06-01
基金资助:
北京市医院管理局“登峰”计划专项(DFL20181401),中国健康促进基金会项目(CHPF-2018-OP-11),国家更年期保健特色专科建设单位项目[(2020)30],首批北京市级妇幼保健专科示范单位“更年期保健专科”项目[(2017)35号]。

Influencing factors of female sexual dysfunction in Chinese women

Ju Rui^1,2, Ruan Xiangyan^1*, Dai Yinmei^1,2, Bai Yongtao³, Yang Yu¹, Xu Xin¹, Cheng Jiaojiao¹, Yang Xingzi³, Shi Yanhong³, Sun Yanhua⁴, Li Ruiling⁴

1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care, Beijing 100026, China;
2. Clinical Trial Institution Office, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care, Beijing 100026, China;
3. Department of Gynecology, Beijing Chaoyang District Taiyanggong Community Health Service Center, Beijing 100028, China;
4. Department of Gynecology, Beijing Chaoyang District Maternal and Child Health Care Hospital, Beijing 100022, China

Received:2022-02-26 Online:2022-06-21 Published:2022-06-01
Contact: *E-mail:ruanxiangyan@ccmu.edu.cn
Supported by:
Beijing Municipal Administration of Hospitals' Ascent Plan(DFL20181401), China Health Promotion Foundation(CHPF-2018-OP-11),National Menopause Health Care Specialist Construction Unit of China[(2020)30],The First Batch of Beijing Maternal and Child Health Specialist Demonstration Units “Menopausal Health Specialist”[(2017)35].

摘要/Abstract

摘要： 目的研究女性性功能障碍(female sexual dysfunction,FSD)的影响因素,为围绝经期和绝经后女性生活质量的改善方法提供临床依据。方法纳入2020年4月至2021年3月在首都医科大学附属北京妇产医院及两家医联体医疗机构就诊的女性902例。收集社会人口学资料、生物学、临床特征和躯体测量指标。根据女性性功能指数(Female Sexual Function Index, FSFI)量表评估FSD将研究对象分为2组:有FSD 和无FSD。根据“生殖衰老研讨会分期+10”将研究对象分期、改良Kupperman评分表(Modified Kupperman Index, KMI)评估更年期症状、心理健康问卷-9量表评价抑郁状态、国际尿失禁咨询委员会尿失禁问卷(International Consultation on Incontinent Questionnaire, ICIQ)量表评估女性压力性尿失禁、膀胱过度活动症评分(Overactive Bladder Symptom Score, OABSS)量表评估膀胱过度活动症。FSD的影响因素应用二元Logistic回归多因素分析。结果多因素分析结果显示:KMI评分(OR=1.061,95%CI:1.039~1.083)、血清卵泡刺激素(follicle stimulating hormone, FSH)(OR=1.008,95%CI:1.002~1.014)、高中以下学历(OR=1.446,95%CI:1.019~2.052)、抑郁(OR=1.814,95%CI:1.156~2.845)、绝经后早期(OR=1.717,95%CI:1.106~2.667)、绝经后晚期(OR=1.905,95%CI:1.008~3.602)、婚姻关系一般(OR=2.422,95%CI:1.711~3.429)和婚姻关系不满意(OR=1.945,95%CI:1.018~3.717)是FSD的重要危险因素(P<0.05);绝经后早期应用芬吗通治疗是FSD的重要保护因素(OR=0.229,95%CI:0.059~0.889,P<0.05)。结论 FSD受心理、生理、社会等多种因素的影响,卵巢衰竭是FSD的重要危险因素,绝经后女性早期应用绝经激素治疗是FSD的保护因素。

关键词: 女性性功能障碍, 影响因素, 生殖衰老分期, 绝经, 激素治疗, 女性性功能指数, 性激素

Abstract: Objective To investigate the risk factors of female sexual dysfunction (FSD) in Chinese women and to provide clinical evidences for improving perimenopausal and postmenopausal women's quality of life. Methods A multicenter clinical study was conducted among 902 women in the Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University and other two medical alliance institutions from April 2020 to March 2021. Socio-demographic, behavioral and clinical data were collected. The anthropometric indices of each subject were measured. FSD were evaluated using the Female Sexual Function Index (FSFI) and the subjects were divided into two groups according to the FSFI: FSD group and no FSD group. According to the 2011 stages of the Reproductive Ageing Workshop (STRAW+10) and postmenopausal women using menopause hormone therapy (MHT) or not, the subjects were divided into seven stages, Modified Kupperman Index (KMI) for climacteric syndromes, The Patient Health Questionnaire-9 (PHQ-9) for depression, the International Consultation on Incontinent Questionnaire (ICIQ) for stress urinary incontinence, the Overactive Bladder Symptom Score (OABSS) for overactive bladder. According to the obtained results, univariate and multivariate Logistic regression analyses were performed. Results Multivariate regression analysis revealed that KMI (OR=1.061,95%CI:1.039-1.083),follicle stimulating hormone (FSH) (OR=1.008,95%CI:1.002-1.014),below secondary education level (OR=1.446,95%CI:1.019-2.052), depress (OR=1.814,95%CI:1.156-2.845), early postmenopausal stage (OR=1.717,95%CI:1.106-2.667), late postmenopausal stage (OR=1.905,95%CI:1.008-3.602), neutral marital relationship (OR=2.422,95%CI:1.711-3.429) and dissatisfaction marital relationship (OR=1.945,95%CI:1.018-3.717) were the important risk factors for FSD (P<0.05). Femoston was the protective factor for FSD in early menopausal women(OR=0.229,95%CI:0.059-0.889) (P<0.05). Conclusion Many psychological, physiological and social factors induce FSD. Ovarian function failure is an important risk factor for FSD. MHT was shown to have a beneficial effect on FSD.

Key words: female sexual dysfunction, risk factor, STRAW+10 criteria, menopause, hormone therapy, FSFI, sex hormone

中图分类号:

R711.75

鞠蕊, 阮祥燕, 代荫梅, 白勇涛, 杨瑜, 许新, 程姣姣, 杨幸子, 施琰红, 孙艳华, 李瑞玲. 女性性功能障碍的影响因素研究[J]. 首都医科大学学报, 2022, 43(3): 357-363.

Ju Rui, Ruan Xiangyan, Dai Yinmei, Bai Yongtao, Yang Yu, Xu Xin, Cheng Jiaojiao, Yang Xingzi, Shi Yanhong, Sun Yanhua, Li Ruiling. Influencing factors of female sexual dysfunction in Chinese women[J]. Journal of Capital Medical University, 2022, 43(3): 357-363.

参考文献

[1] Heidari M, Sheikhi R A, Rezaei P, et al. Comparing quality of Life of elderly menopause living in urban and rural areas[J]. J Menopausal Med, 2019, 25(1): 28-34.
[2] 朱兰, 娄文佳. 重视女性性功能障碍疾病[J]. 实用妇产科杂志, 2018, 34(6): 401-402.
[3] American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. Female sexual dysfunction: ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists, number 213[J]. Obstet Gynecol, 2019, 134(1): e1-e18.
[4] Ju R, Ruan X Y, Xu X, et al. Importance of active and passive smoking as one of the risk factors for female sexual dysfunction in Chinese women[J]. Gynecol Endocrinol, 2021, 37(6): 541-545.
[5] 鞠蕊, 阮祥燕, 代荫梅, 等. 不同生殖衰老分期及激素替代治疗的绝经期女性性功能障碍状况分析[J]. 首都医科大学学报, 2021, 42(4): 533-539.
[6] 鞠蕊, 阮祥燕, 许新, 等. 围绝经期及绝经后女性性功能障碍状况及与更年期症状的关系分析[J]. 首都医科大学学报, 2020, 41(4): 503-507.
[7] Harlow S D, Gass M, Hall J E, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging[J]. Climacteric, 2012, 15(2): 105-114.
[8] Sun X G, Li C Y, Jin L N, et al. Development and validation of Chinese version of female sexual function index in a Chinese population: a pilot study[J]. J Sex Med, 2011, 8(4): 1101-1111.
[9] Williams L S, Brizendine E J, Plue L, et al. Performance of the PHQ-9 as a screening tool for depression after stroke[J]. Stroke, 2005, 36(3): 635-638.
[10] Blaivas J G, Panagopoulos G, Weiss J P, et al. Validation of the overactive bladder symptom score[J]. J Urol, 2007, 178(2): 543-547.
[11] Thomas H N, Neal-Perry G S, Hess R. Female sexual function at midlife and beyond[J]. Obstet Gynecol Clin North Am, 2018, 45(4): 709-722.
[12] McCool-Myers M, Theurich M, Zuelke A, et al. Predictors of female sexual dysfunction: a systematic review and qualitative analysis through gender inequality paradigms[J]. BMC Womens Health, 2018, 18(1): 108.
[13] 金凤羽, 阮祥燕, Alfred O M, 等. 北京及周边地区围绝经期女性性功能现状调查分析[J]. 首都医科大学学报, 2017, 38(4): 509-514.
[14] Tong J, Zhang C, Zhu L, et al. Sexual dysfunction in perimenopausal women based on a national epidemiological survey in China[J]. Climacteric, 2019, 22(2): 190-194.
[15] Lou W J, Chen B, Zhu L, et al. Prevalence and factors associated with female sexual dysfunction in Beijing, China[J]. Chin Med J (Engl), 2017, 130(12): 1389-1394.
[16] Heidari M, Ghodusi M, Rezaei P, et al. Sexual function and factors affecting menopause: a systematic review[J]. J Menopausal Med, 2019, 25(1): 15-27.
[17] Kong F, Wang J, Zhang C, et al. Assessment of sexual activity and menopausal symptoms in middle-aged Chinese women using the Menopause Rating Scale[J]. Climacteric, 2019, 22(4): 370-376.
[18] Baber R J, Panay N, Fenton A, et al. 2016 IMS recommendations on women's midlife health and menopause hormone therapy[J]. Climacteric, 2016, 19(2): 109-150.
[19] Weinberger J M, Houman J, Caron A T, et al. Female sexual dysfunction: a systematic review of outcomes across various treatment modalities[J]. Sex Med Rev, 2019, 7(2): 223-250.
[20] Laumann E O, Paik A, Glasser D B, et al. A cross-national study of subjective sexual well-being among older women and men: findings from the Global Study of Sexual Attitudes and Behaviors[J]. Arch Sex Behav, 2006, 35(2): 145-161.
[21] Jiann B P, Su C C, Yu C C, et al. Risk factors for individual domains of female sexual function[J]. J Sex Med, 2009, 6(12): 3364-3375.
[22] Shifren J L, Monz B U, Russo P A, et al. Sexual problems and distress in United States women: prevalence and correlates[J]. Obstet Gynecol, 2008, 112(5): 970-978.
[23] Zhang H P, Yip P S F. Female sexual dysfunction among young and middle-aged women in Hong Kong: prevalence and risk factors[J]. J Sex Med, 2012, 9(11): 2911-2918.
[24] Cappelletti M, Wallen K. Increasing women's sexual desire: the comparative effectiveness of estrogens and androgens[J]. Horm Behav, 2016, 78: 178-193.
[25] Ruan X Y, Mueck A O. Chinese obstetrician-gynecologists still need more education in menopausal hormone therapy[J]. Menopause, 2014, 21(11): 1170-1172.
[26] Stevenson J C, Panay N, Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety[J]. Maturitas, 2013, 76(1): 10-21.

女性性功能障碍的影响因素研究

Influencing factors of female sexual dysfunction in Chinese women

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	齐涵, 贾鹏举, 王春燕, 胡维明, 付晨光, 夏晨妮, 姜涛, 吴曼琴, 王学好, 张长春, 闫芳. 心理健康教育对北京市养老机构老年人的干预效果及其影响因素[J]. 首都医科大学学报, 2023, 44(1): 27-34.
[2]	王映权, 冯琳, 左颖婷, 童朝晖, 梁立荣. 慢性阻塞性肺疾病急性加重临床路径的实施及影响因素[J]. 首都医科大学学报, 2023, 44(1): 35-41.
[3]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[4]	许新, 阮祥燕, 鞠蕊, 杨瑜, 程姣姣, 王志坤, Alfred O. Mueck. 中国女性轻度认知障碍的影响因素及其与绝经症状的关系[J]. 首都医科大学学报, 2022, 43(3): 369-374.
[5]	宋丽敏, 李思源, 李军, 赵会荣, 李佳佳, 王双. 新疆石河子地区绝经后2型糖尿病女性SOST基因联合LRP5基因多态性及突变与骨代谢关系的研究[J]. 首都医科大学学报, 2022, 43(2): 269-274.
[6]	李云飞, 夏恩兰, 黄晓武. 绝经后异常子宫出血患者的临床与病理分析[J]. 首都医科大学学报, 2021, 42(6): 1060-1064.
[7]	姚懿, 唐晓芳, 宋莹, 姜琳, 乔树宾, 袁晋青. 急性冠状动脉综合征患者抗血小板药物抵抗的影响因素分析[J]. 首都医科大学学报, 2021, 42(5): 799-803.
[8]	苗芳芳, 冯雪辛, 侯瑞雪, 段庆芳, 王天龙. 神经外科手术患者术后排气时间影响因素分析[J]. 首都医科大学学报, 2021, 42(5): 816-821.
[9]	鞠蕊, 阮祥燕, 代荫梅, 白勇涛, 杨幸子, 施琰红, 许新, 杨瑜, 程姣姣, 孙艳华, 李瑞玲. 不同生殖衰老分期及激素替代治疗的绝经期女性性功能障碍状况分析[J]. 首都医科大学学报, 2021, 42(4): 533-539.
[10]	仪玉伟, 闫芳, 靳玉宏, 肖存利. 精神分裂症住院患者危险行为的影响因素分析[J]. 首都医科大学学报, 2021, 42(2): 323-327.
[11]	鞠蕊, 阮祥燕, 许新, 杨瑜, 张露平, 秦爽, 王宾红, 豆竹丽, Alfred O. Mueck. 围绝经期及绝经后女性性功能障碍状况及与更年期症状的关系分析[J]. 首都医科大学学报, 2020, 41(4): 503-507.
[12]	王宾红, 阮祥燕, 鞠蕊, 豆竹丽, 秦爽, 张露平, 许新, 杨瑜, Alfred O. Mueck. 综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响[J]. 首都医科大学学报, 2020, 41(4): 520-524.
[13]	秦爽, 阮祥燕, 王宾红, 鞠蕊, 张露平, 豆竹丽, 程姣姣, 金婧. 多囊卵巢综合征患者促排卵周期中成熟卵泡性激素浓度对妊娠的影响[J]. 首都医科大学学报, 2020, 41(4): 530-535.
[14]	王月姣, 阮祥燕, 谷牧青, 蔡桂举, 李雪, 张凌燕, Alfred O. Mueck. 他莫昔芬治疗乳腺癌异种移植瘤裸鼠子宫病理改变[J]. 首都医科大学学报, 2019, 40(4): 539-543.
[15]	孙琦, 王皓, 刘洪琪, 王友信. 2017年潍坊市某高校新生亚健康状态及影响因素分析[J]. 首都医科大学学报, 2019, 40(2): 276-281.